MCL1 and non-Hodgkin lymphoma: The CDK inhibitor flavopiridol has been assessed clinically in NHL patients37, 38, 39, 40 and is a transcriptional repressor of MCL-1 expression.41, 42 We have demonstrated that A-1210477 induces a cellular phenotype similar to that observed following repression of MCL-1 expression through inhibition of transcriptional elongation by flavopiridol.27 Flavopiridol therefore represents a clinically relevant surrogate for inhibiting MCL-1 function.